Jared Moss, MD
Urology · Shreveport, LANPI 1548571185
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.8%), consulting fees and education — rather than concentrated in one kind of arrangement. Coloplast accounts for 86.7% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2022 at $5,375 and has fallen 66.8% since, to $1,785 in 2025. Among urology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 338 payments — averaging $50.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$15K
- Boston Scientific$440
- Endo Pharmaceuticals Inc.$263
- Pfizer$185
- Medtronic$173
- Astellas Pharma US Inc$147
- plus $1K from 22 others
Across 54 payments — averaging $6452.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Laborie Medical Technologies Corp.$344K
- Urotronic, Inc$4K
What the payments were for
- Consulting fees$4,95029%
- Travel & lodging$1251%
- Food & beverage$7,07742%
- Education$4,76428%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 237 | $14,668 |
| Boston Scientific | 12 | $440 |
| Endo Pharmaceuticals Inc. | 13 | $263 |
| Pfizer | 14 | $185 |
| Medtronic(2 entities) | 4 | $173 |
| Astellas Pharma US Inc | 12 | $147 |
| Endo USA, Inc. | 8 | $144 |
| Cook Medical LLC | 2 | $108 |
| Koelis Inc. | 1 | $99 |
| Ferring Pharmaceuticals Inc. | 4 | $96 |
| AbbVie(2 entities) | 7 | $92 |
| Siemens Medical Solutions USA, Inc. | 1 | $66 |
| Laborie Medical Technologies Corp. | 4 | $59 |
| Blue Earth Diagnostics | 2 | $48 |
| Calyxo, Inc. | 2 | $48 |
| Teleflex LLC | 2 | $37 |
| AstraZeneca | 1 | $35 |
| Progenics Pharmaceuticals, Inc. | 1 | $30 |
| Travere Therapeutics, Inc. | 2 | $29 |
| Amgen | 1 | $22 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $21 |
| Galderma Laboratories, L.p. | 1 | $19 |
| Dendreon Pharmaceuticals LLC | 1 | $18 |
| Urogen Pharma, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Urovant Sciences Inc | 1 | $14 |
| Amniox Medical, Inc. | 1 | $14 |
| Tolmar, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,916 in reported general payments places this provider in the 90th percentile of 199 urology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 81 | $78,798 |
| Tamsulosin Hcl | 637 | $10,526 |
| Testosterone Cypionate | 230 | $9,541 |
| Testosterone | 24 | $4,779 |
| Finasteride | 275 | $3,752 |
| Oxybutynin Chloride ErOxybutynin Chloride | 68 | $2,521 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 109 | $2,165 |
| Dutasteride | 54 | $2,130 |
| Potassium Citrate ErPotassium Citrate | 23 | $1,905 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 100 | $1,898 |
| Solifenacin Succinate | 31 | $467 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 15 | $457 |
| Terazosin Hcl | 24 | $389 |
| Doxazosin Mesylate | 16 | $258 |
| Meloxicam | 100 | $233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $147 | $78,79881 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 199 urology providers in Louisiana.
Other urology in Shreveport
- Ralph HendersonShreveport$211K
- Kevin HebertShreveport$54K
- Nazih KhaterShreveport$23K
- David PriceShreveport$23K
- Tajammul FaziliShreveport$16K
- Ashley BakerShreveport$13K
- Kevin ClineShreveport$12K
- Adam StageShreveport$8K
- Jeremy NorwoodShreveport$8K
- Richard VanlangendonckNew Orleans$289K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.